Novo Nordisk Moves Into Renal Disease Via Pact With Omeros

 
• By Joseph Haas
  
Novo Nordisk
Novo Nordisk's 10th deal of 2025 brings a renal rare disease candidate • Source: Shutterstock

More from Deals

More from Business